Please ensure Javascript is enabled for purposes of website accessibility

Here’s Why Momenta Pharmaceuticals Stock Dropped Today

By Brian Orelli, PhD - Dec 11, 2019 at 3:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are worried about the biotech raising cash.

What happened

Shares of Momenta Pharmaceuticals (MNTA) were down 14% at 3:20 p.m. EST on Wednesday following Tuesday's announcement that the biotech plans to raise $200 million, with the potential for $30 million more, by selling additional shares.

So what

It's fairly common for shares to drop after the announcement of a secondary offering. Current shareholders will be diluted when the additional shares are issued, resulting in each share representing a smaller fraction of the company. And secondary buyers typically want a discount to the trading price, so investors today are anticipating the likely change in valuation.

Momenta Pharmaceuticals ended the third quarter with a little over $325 million in the bank, which isn't a terribly long runway for a company that isn't profitable and is a few years away from getting its next drug on the market.

With shares at a 52-week high, now is the right time for Momenta to raise additional cash. By selling at a higher share price, the company can sell fewer shares to raise the same amount of cash, thus limiting the dilution of current shareholders.

Magnifying glass and pen on a balance sheet

Image source: Getty Images.

Now what

The share price that the institutional investors who buy the secondary offering are willing to pay will set Momenta's valuation in the short term. It's entirely possible it'll be lower than where the stock closes today.

Longer term, biotech stocks are valued on the success of their pipeline. For Momenta, that's mainly nipocalimab, which is being tested for three different autoimmune diseases. Results from the first mid-stage study in a disease called generalized myasthenia gravis are expected in the second or third quarter of next year, so investors won't have to wait too long for an early indication of Momenta's pipeline potential.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Momenta Pharmaceuticals, Inc. Stock Quote
Momenta Pharmaceuticals, Inc.
MNTA

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.